Clinical Trial Detail

NCT ID NCT04062708
Title CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alliance Foundation Trials, LLC.
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Docetaxel + Durvalumab

Durvalumab

Cisplatin + Durvalumab + Pemetrexed Disodium

Age Groups: adult senior

No variant requirements are available.